Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ:BFRA) and Medac Gesellschaft für klinische Spezialpräparate mbH have signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland.
- The agreement has a term of 5 years commencing with the start of sales in Poland.
- Under the terms of the agreement, Medac will make an immediate one-time upfront payment of €50,000, plus an additional one-time payment of €150,000 after the drug's reimbursement eligibility in Poland.
- In 2011, Ameluz was approved for photodynamic therapy (PDT) of mild to moderate actinic keratoses, field cancerization, and superficial and nodular basal cell carcinomas.
- Ameluz is approved for use in conventional PDT with red-light lamp BF-RhodoLED as well as for daylight PDT.
- Price Action: BFRA shares are up 1.7% at $6.55 during the premarket session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!